Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

78009

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Radiotherapy
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, for what reason none of the £42 million his Department has made available for increasing the use of radiotherapy is to be spent on treating cancer patients with Stereotactic Ablative Radiotherapy this year.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	205834
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>In July 2011, the National Radiotherapy Implementation Group concluded that current evidence supports treatment withstereotactic ablative radiotherapy (SABR) for only a small number of patients. The evidence supports its use in the treatment of early stage lung cancers for patients who are unsuitable for surgery (approximately 1,000 per annum).</p><p> </p><p>NHS England recognises the positive clinical impact that its national policy on SABR for the treatment of early non-small cell lung cancer has had. It is currently examining the potential use of SABR in patients with oligometastatic disease – where a cancer is in the early stages of spreading.</p><p> </p><p>NHS England is also currently undertaking a review of stereotactic radiosurgery (SRS) and SABR for intracranial conditions to establish what the national demand is in line with its national clinical commissioning policies on SRS and SABR, and what the national capacity requirements are for this specialised treatment. Following the review it is planned that a final decision will be taken by the Specialised Commissioning Oversight Group in October 2014.</p><p> </p><p>Later this year, the Radiotherapy Clinical Reference Group will review its current policy position on SABR to assess whether there is new evidence to recommend its use on other conditions. It is important to ensure that treatments commissioned are supported by robust evidence of their benefit to patients.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 22/07/2014 13:47:28 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt

78017

registered interest
date	15/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Monitor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, to what extent NHS England is obliged to follow guidance issued by Monitor.
tabling member constituency	Wells
tabling member printed	Tessa Munt
uin	205780
answer	answer is ministerial correction date of answer 22/07/2014 answer text <p>It is the National Health Service (Procurement, Patient Choice and Competition) (No. 2) Regulations 2013 that place requirements on NHS England, including requirements as to good practice in relation to procurement.</p><p> </p><p>Enforcement of the procurement requirements by Monitor may only follow its investigation of a complaint that there has been a failure by a commissioner to comply with the requirements. Monitor has published guidance for NHS England and other commissioners of healthcare services which provides advice on how to comply with the regulations. Monitor expects to follow the interpretation of the regulations that it has set out in its guidance when exercising its enforcement powers under the regulations.</p><p> </p><p>In addition, to the extent that NHS England acts as a commissioner of services, it has a legal duty to have regard to guidance which Monitor publishes for commissioners of services which are designated as ‘commissioner requested services’. Before publishing the guidance or any revisions to it, Monitor must have first consulted NHS England.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 22/07/2014 16:03:53 answering member 3918 label Biography information for Jane Ellison
tabling member	4089 label Biography information for Tessa Munt